FIGS · FIGS, Inc. · Stock research

Current Thesis

A 2021 direct-to-consumer IPO that stalled for three years has re-accelerated, and the market repriced it in a single session. Q2 2026, reported 2026-08-06: net revenue $196.6M, +28.8% YoY, against $185.855M consensus; diluted EPS $0.15 against $0.07 estimated; FY2026 revenue guidance lifted to $757.318M from a prior $719.452M–$732.074M band (consensus $729.093M); the repurchase authorization raised by $100M to $200M. That is the leg an investor is buying: durability of a growth re-acceleration in a category — healthcare apparel — with no obvious cyclical substitute.

The hazard sits in the same release. Gross margin printed 75.2%, up 820bp YoY, and 780bp of that expansion was attributed to $7.9M of IEEPA tariff refunds recognized in the quarter. The margin headline that drove the re-rating does not annualize on its own terms, and management noted non-IEEPA tariffs moved higher. Two sessions of price action is not a base.

Bullish and bearish views on FIGS, Inc.

The model's bull view on FIGS, Inc. (FIGS), in brief: Q2 2026 (2026-08-06): net revenue $196.6M, +28.8% YoY, beating the $185.855M consensus by roughly $10.5M; diluted EPS $0.15 vs $0.07 estimated. The bear view: The margin line is contaminated. Of the 820bp of gross-margin expansion to 75.2%, 780bp was attributed to $7.9M of IEEPA tariff refunds — a recognition event, not a run-rate. Q3 is the first period without that contribution in the comparison. Dispersion, on the same day, off the… Both cases follow in full.

Bull Case

• Q2 2026 (2026-08-06): net revenue $196.6M, +28.8% YoY, beating the $185.855M consensus by roughly $10.5M; diluted EPS $0.15 vs $0.07 estimated.
• Third consecutive quarter of 25%+ revenue growth, per the Q2 2026 earnings materials.
• FY2026 revenue growth outlook raised to approximately 20% from a prior 14–16%; adjusted EBITDA margin outlook to 14.8–15.0% from 13.0–13.2%; operating margin outlook to approximately 10.8% from 7.8–8.0%.
• Unit economics improved without a promotional giveback: active customers 3.1M on a trailing-twelve-month basis, +13.2% YoY; average order value a record $127, +8.5%; revenue per active customer $229, +10% YoY.
• International was 19% of Q2 sales and grew 67% YoY, with the served-country count expanded from 58 to 85. U.S. (81% of sales) still grew 22%.
• Mix is broadening: non-scrubwear reached 18% of revenue at +40% YoY versus scrubwear +27%.
• Cash generation turned: H1 2026 free cash flow $38.6M against -$5.6M in the prior-year half. Cash, equivalents and short-term investments $296.3M, +24% YoY ($108.5M cash and equivalents plus $187.8M short-term investments at quarter end).
• Capital return is active rather than announced-and-idle: $32.8M repurchased in H1 2026, of which $24M in Q2, before the authorization was doubled on 2026-08-06.
• Sell-side moved on 2026-08-07: BTIG raised its target to $22 (Buy), KeyBanc to $20 (Overweight). S&P Global's polled consensus across 9 analysts sits at $17.63, high $22, low $14.

Bear Case

• The margin line is contaminated. Of the 820bp of gross-margin expansion to 75.2%, 780bp was attributed to $7.9M of IEEPA tariff refunds — a recognition event, not a run-rate. Q3 is the first period without that contribution in the comparison.
• Dispersion, on the same day, off the same information: Telsey Advisory Group held Market Perform and lowered its target to $16 on 2026-08-07 while BTIG and KeyBanc raised. The published target range spans $14 to $22.
• The stock is repairing damage rather than making new highs. At the 2026-08-07 close of $14.26 it remains 16.7% below the $17.12 52-week high, and the three-month return is +22.6% — most of it delivered in one gap.
• Precedent from this year cuts against automatic follow-through: the Q1 2026 print on 2026-05-07 beat and shares fell.
• RSI(14) reached 81.9 at the 2026-08-07 close.
• Concentration: scrubwear was 82% of Q2 revenue. Demand is a replacement cycle levered to healthcare headcount, and a slowdown there has no offset elsewhere in the mix.
• Physical retail is being added to a 75%-gross-margin DTC model: five Community Hubs operational, four additional openings planned for H2 2026, each carrying fixed occupancy and staffing cost.

Setup & Price Structure

• Pipeline basis: last completed daily close $14.26 on 2026-08-07. 52-week high $17.12, distance -16.7%. Three-month return +22.6%. RSI(14) 81.9.
• The entire re-rating is one event. Investing.com reported the shares +24.56% in the 2026-08-06 after-hours session to $14.00. On 2026-08-07 the name appeared in Benzinga's consumer-discretionary pre-market movers list alongside eleven other tickers.
• Life-cycle: ACCELERATING, dated by 2026-08-06 (beat, guidance raise, buyback doubled) and 2026-08-07 (three target revisions the following morning, pre-market movers coverage). New attention, fresh headlines, and a guidance range that moved rather than a multiple that drifted. The qualifier is sample size: two sessions establish a gap, not a shelf, and there is no post-gap consolidation to measure participation against.
• Crowding and positioning observables, stated as observables: RSI(14) 81.9 at the last close; price extended well above any pre-print range yet still 16.7% under the 52-week high; short interest of 17.6M shares, 11.6% of float, up 144.9% since July 2025 per fintel.io as retrieved 2026-08-09 (a settlement-date figure, so it lags the gap and does not yet show covering); the issuer buying its own stock — $32.8M in H1 2026 with authorization raised to $200M — rather than issuing into strength; no scheduled company earnings event inside the next 30 days. A Form 4 record of insider sales into the move was not located as of 2026-08-09; absence of a search result is not evidence of absence.
• Structure to watch: the 2026-08-06 gap is unfilled and untested. Whether the name holds a range above the pre-print zone through the back half of August is the first read on whether the bid is broader than event-driven covering.

Catalyst Calendar (next 30 days)

• ~2026-08-26 (est.) — FINRA semi-monthly short-interest publication covering the 2026-08-14 settlement date. First measurement of whether the 11.6%-of-float short base covered into the gap or was rebuilt higher.
• ~2026-09-04 (est.) — August U.S. employment report. Healthcare and ambulatory-services payroll detail is the highest-frequency proxy for the end-market headcount behind scrub demand.
• ~2026-09-10 (est.) — FINRA short-interest publication for the 2026-08-31 settlement date. Second reading; a two-point series is where the covering-versus-rebuild question starts to resolve.
• No company-scheduled event falls inside the window. The next binary is the Q3 2026 print, historically early November (~2026-11-05, est.); FIGS announced its Q2 date on 2026-07-16, roughly three weeks ahead, so the Q3 date announcement likely lands mid-October and also outside the window.

What Would Change Our Mind

The structural break is the 2026-08-06 gap being handed back. That gap is the whole of the re-rating; if it fills, the market has decided Q2 was a tariff-refund quarter with a growth headline attached. Concretely: a weekly close below $12.00 surrenders the bulk of the post-print move and removes the price evidence that the guidance raise was believed.

The fundamental break is separate and slower. The FY2026 guide is $757.318M, approximately 20% growth; any trim to that number, or a Q3 gross margin that compresses sharply once the $7.9M IEEPA refund is out of the comparison, would reframe Q2 as a single-quarter event. A third condition: the theme flipping to SATURATED — target revisions stopping, coverage thinning, the name no longer surfacing in movers lists while price stalls under the $17.12 52-week high — would mean the accelerating leg has already been paid for.

Correlation Notes

• Demand is levered to healthcare employment rather than general apparel spend: 82% of Q2 revenue was scrubwear. The monthly BLS payroll detail on healthcare and ambulatory hiring is the closest high-frequency read on the customer base; broad discretionary retail sales data is a weaker proxy.
• Trade policy runs straight through the P&L. The $7.9M IEEPA refund in Q2 means tariff litigation and CBP refund timing hit the gross-margin line before they touch revenue, and the company flagged higher non-IEEPA tariffs in the same quarter.
• FX matters more than it did: international was 19% of Q2 sales growing 67% YoY across 85 countries, so dollar strength compresses reported international growth.
• Squeeze-cohort beta is present. At 11.6% of float short, the name will move with heavily shorted small- and mid-cap consumer names on covering days. A 2026-07-13 Benzinga "Squeeze Watch" item on the most heavily shorted names surfaced in FIGS's news feed; the examples that piece named were Lucid, Figma, SoundHound and Ondas.
• As an NYSE-listed small cap in consumer discretionary, rotation into small-cap and specialty-retail baskets is a second-order flow input independent of company news.